Patients with relapsing-remitting multiple sclerosis (RRMS) who switch to Tysabri (natalizumab) after relapses on first-line treatment with other medications show greater relapse reduction and less disability progression than those switching to Gilenya (fingolimod), according to a real-world study.
The research, “Comparative effectiveness of switching to natalizumab or fingolimod after relapse on first-line relapsing-remitting multiple sclerosis therapy: propensity score matching analysis from the MSBase registry,” was presented Oct. 10 at the 34th congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) in Berlin, Germany.
RRMS patients who relapse while on first-line treatment with formulations of interferon — such as Avonex (by Biogen), Rebif (by EMD Serono), and Betaferon/Betaseron by Bayer) – glatiramer acetate (Copaxone by Teva Pharmaceuticals), dimethyl fumarate (Tecfidera by Biogen), or teriflunomide (Aubagio by Sanofi Genzyme), collectively known as “BRACETD,” may benefit from switching therapies.
Aiming to address this gap, a team from Australia, Czech Republic, Spain, Italy, Canada, Portugal, Turkey, and Belgium compared the effectiveness of switching to either medication after one or more relapses in RRMS patients on BRACETD.
The patients were selected from the MSBase Neuro-Immunology Registry, which currently contains 61,898 patient records from 128 clinics in 34 countries.
Participants were divided into groups and subgroups based on the number of relapses in the year before switching treatment. Group 1 had one or more relapses (all the patients). Out of that, group 2 had two or more relapses, group 3 had only one relapse, and group 4 included patients with one relapse in the prior year but one or more in 12-24 months prior to switching (patients with persistently active disease).
We are sorry that this post was not useful for you!
Let us improve this post!
Tell us how we can improve this post?